Just last month, the Food and Drug Administration (FDA) approved Eli Lillys injectable Zepbound on November 8 specifically for chronic weight management in people with obesity or who are overweight
Searching the identifier NCT05934110 provides details on the primary Phase 3 program
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
Do not stop your prescribed medication without medical advice
Sucic et al., 2019) occurred in both ischemic and reperfusion conditions in various tissues (i.e., colon, duodenum, cecum, liver, and veins) and plasma, in vessel occlusion studies in particular (Vukojevic et al., 2018
90 capsules, clean form 14,00 incl
/assets/images/provider/photos/2814339.jpeg)
